| pubmed-article:8453693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C1261473 | lld:lifeskim |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C0262950 | lld:lifeskim |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8453693 | lifeskim:mentions | umls-concept:C1512018 | lld:lifeskim |
| pubmed-article:8453693 | pubmed:dateCreated | 1993-4-22 | lld:pubmed |
| pubmed-article:8453693 | pubmed:abstractText | We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985. All the studies have used either N-acetyl-L-cysteine (NAC) or mesna as a uroprotective agent, except in one arm of one study where hydration alone was employed. Mesna has proven superior to NAC in providing protection against ifosfamide-induced hematuria. Mesna given as a loading dose followed by continuous 24-h infusion has been effective and most practical in this regard. Ifosfamide has demonstrated clinically useful antitumor activity in our hands against most sarcoma subtypes. Our studies suggest a dose-response relationship for ifosfamide. At a total dose of 6 g/m2 per course, the overall response rate was 10%; at 10 g/m2 per course, it rose to 21%. Future clinical trials will determine ifosfamide's role in combination chemotherapy and more clearly define the best schedule or schedules for the uroprotective administration of mesna. | lld:pubmed |
| pubmed-article:8453693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8453693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8453693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8453693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8453693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8453693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8453693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8453693 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:8453693 | pubmed:author | pubmed-author:LeghaS SSS | lld:pubmed |
| pubmed-article:8453693 | pubmed:author | pubmed-author:BenjaminR SRS | lld:pubmed |
| pubmed-article:8453693 | pubmed:author | pubmed-author:PatelS RSR | lld:pubmed |
| pubmed-article:8453693 | pubmed:author | pubmed-author:NicaiseCC | lld:pubmed |
| pubmed-article:8453693 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8453693 | pubmed:volume | 31 Suppl 2 | lld:pubmed |
| pubmed-article:8453693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8453693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8453693 | pubmed:pagination | S174-9 | lld:pubmed |
| pubmed-article:8453693 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:meshHeading | pubmed-meshheading:8453693-... | lld:pubmed |
| pubmed-article:8453693 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8453693 | pubmed:articleTitle | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. | lld:pubmed |
| pubmed-article:8453693 | pubmed:affiliation | Department of Melanoma-Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030. | lld:pubmed |
| pubmed-article:8453693 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8453693 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
